Physician profile
Ray R Glendrange
NPI 1164484507
$3,048.57
in general payments reported to CMS, 2019-2025
18 companies · $946 in 2025
The $946 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $104 · 2021: $500 · 2022: $284 · 2023: $173 · 2024: $681 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $975.20 | 2019-2025 | Clareon, Tryptyr, Luxor |
| Abbvie INC. | $571.25 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $210.44 | 2019-2021 | |
| Horizon Therapeutics Plc | $149.29 | 2021 | |
| Bausch & Lomb Americas INC. | $143.18 | 2024-2025 | Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $141.49 | 2021-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Allergan, INC. | $134.22 | 2021 | |
| Oyster Point Pharma, INC. | $132.92 | 2022-2024 | Tyrvaya |
| Braeburn INC. | $119.31 | 2025 | Brixadi |
| Alkermes, INC. | $99.82 | 2024 | Vivitrol |
| Mallinckrodt Hospital Products INC. | $96.66 | 2022-2025 | Acthar |
| Harrow Eye, LLC | $63.31 | 2024-2025 | Vevye |
| Amgen INC. | $57.19 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Glaukos Corporation | $38.46 | 2024 | Idose |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $34.70 | 2022 | |
| Shire North American Group INC | $22.26 | 2019 | |
| Sight Sciences, INC. | $20.07 | 2025 | Sion Surgical Instrument, Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Glendrange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.